Apolipoprotein E genotypes modulate fibrosis progression in patients with chronic hepatitis C and persistently normal transaminases

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 2, 2011, Pages 328-333

  Fabris, Carlo ^a   Vandelli, Carmen ^b   Toniutto, Pierluigi ^a   Minisini, Rosalba ^c   Colletta, Cosimo ^d   Falleti, Edmondo ^a   Smirne, Carlo ^c   Pirisi, Mario ^c  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^d Madonna del Popolo Hospital   (Italy)

Author keywords

Apolipoprotein E; Hepatitis C; Liver fibrosis

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN E; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ALLELE; ARTICLE; BODY MASS; CHILD; CHOLESTEROL BLOOD LEVEL; DISEASE COURSE; DNA POLYMORPHISM; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SCHOOL CHILD;

EID: 78851469467     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06403.x     Document Type: Article

References (35)

1. Afdhal NH. The natural history of hepatitis C. Semin. Liver Dis. 2004; 24 (Suppl. 2): 3-8.
2. Feld JJ, Liang TJ. Hepatitis C-identifying patients with progressive liver injury. Hepatology 2006; 43: S194-206.
3. Massard J, Ratziu V, Thabut D etal. Natural history and predictors of disease severity in chronic hepatitis C. J. Hepatol. 2006; 44: S19-24.
4. Minisini R, Fabris C, Toniutto P, Pirisi M. Combinatorial use of single nucleotide polymorphisms to help predict liver fibrosis in patients with hepatitis C infections. Exp. Opin. Med. Diagnostics. 2009; 3: 355-70.
5. Mathurin P, Moussalli J, Cadranel JF etal. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998; 27: 868-72.
6. Martinot-Peignoux M, Boyer N, Cazals-Hatem D etal. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology 2001; 34: 1000-5.
7. Persico M, Perrotta S, Persico E etal. Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10years. J. Viral Hepat. 2006; 13: 290-6.
8. Puoti C. HCV carriers with persistently normal aminotransferase levels: normal does not always mean healthy. J. Hepatol. 2003; 38: 529-32.
9. Puoti C, Castellacci R, Montagnese F etal. Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC). J. Hepatol. 2002; 37: 117-23.
10. Alberti A, Noventa F, Benvegnu L, Boccato S, Gatta A. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann. Intern. Med. 2002; 137: 961-4.
11. Hui CK, Belaye T, Montegrande K, Wright TL. A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. J. Hepatol. 2003; 38: 511-17.
12. Kumada T, Toyoda H, Kiriyama S etal. Incidence of hepatocellular carcinoma in hepatitis C carriers with normal alanine aminotransferase levels. J. Hepatol. 2009; 50: 729-35.
13. Price DA, Bassendine MF, Norris SM etal. Apolipoprotein epsilon3 allele is associated with persistent hepatitis C virus infection. Gut 2006; 55: 715-18.
14. Wozniak MA, Itzhaki RF, Faragher EB, James MW, Ryder SD, Irving WL. Apolipoprotein E-epsilon 4 protects against severe liver disease caused by hepatitis C virus. Hepatology 2002; 36: 456-63.
15. Toniutto P, Fabris C, Fumo E etal. Carriage of the apolipoprotein E-epsilon4 allele and histologic outcome of recurrent hepatitis C after antiviral treatment. Am. J. Clin. Pathol. 2004; 122: 428-33.
16. Fabris C, Toniutto P, Bitetto D etal. Low fibrosis progression of recurrent hepatitis C in apolipoprotein E epsilon4 carriers: relationship with the blood lipid profile. Liver Int. 2005; 25: 1128-35.
17. Ishak K, Baptista A, Bianchi L etal. Histological grading and staging of chronic hepatitis. J. Hepatol. 1995; 22: 696-9.
18. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 1999; 94: 2467-74.
19. Zivelin A, Rosenberg N, Peretz H, Amit Y, Kornbrot N, Seligsohn U. Improved method for genotyping apolipoprotein E polymorphisms by a PCR-based assay simultaneously utilizing two distinct restriction enzymes. Clin. Chem. 1997; 43: 1657-9.
20. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988; 240: 622-30.
21. Weisgraber KH, Rall SC Jr, Mahley RW. Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J. Biol. Chem. 1981; 256: 9077-83.
22. Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am. J. Epidemiol. 2002; 155: 487-95.
23. Malloy SI, Altenburg MK, Knouff C, Lanningham-Foster L, Parks JS, Maeda N. Harmful effects of increased LDLR expression in mice with human APOE*4 but not APOE*3. Arterioscler. Thromb. Vasc. Biol. 2004; 24: 91-7.
24. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc. Natl. Acad. Sci. U. S. A. 1999; 96: 12766-71.
25. Pumeechockchai W, Bevitt D, Agarwal K etal. Hepatitis C virus particles of different density in the blood of chronically infected immunocompetent and immunodeficient patients: implications for virus clearance by antibody. J. Med. Virol. 2002; 68: 335-42.
26. Cattin L, Fisicaro M, Tonizzo M etal. Polymorphism of the apolipoprotein E gene and early carotid atherosclerosis defined by ultrasonography in asymptomatic adults. Arterioscler. Thromb. Vasc. Biol. 1997; 17: 91-4.
27. Gomez-Coronado D, Alvarez JJ, Entrala A, Olmos JM, Herrera E, Lasuncion MA. Apolipoprotein E polymorphism in men and women from a Spanish population: allele frequencies and influence on plasma lipids and apolipoproteins. Atherosclerosis 1999; 147: 167-76.
28. Boccato S, Pistis R, Noventa F, Guido M, Benvegnu L, Alberti A. Fibrosis progression in initially mild chronic hepatitis C. J. Viral Hepat. 2006; 13: 297-302.
29. Puoti C, Stati T, Magrini A, Serum HCV. RNA titer does not predict the severity of liver damage in HCV carriers with normal aminotransferase levels. Liver 1999; 19: 104-9.
30. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48: 418-31.
31. Bochud PY, Cai T, Overbeck K etal. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J. Hepatol. 2009; 51: 655-66.
32. Puoti C. HCV carriers with persistently normal ALT levels: not too much healthy, not true patients. Rom. J. Gastroenterol. 2004; 13: 329-32.
33. Ye J. Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virus. PLoS Pathog. 2007; 3: e108.
34. Gopal K, Johnson TC, Gopal S etal. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology 2006; 44: 335-40.
35. Sheridan DA, Price DA, Schmid ML etal. Apolipoprotein B-associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti-viral agents interferon-alpha and ribavirin. Aliment. Pharmacol. Ther. 2009; 29: 1282-90.